Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer

Fig. 4

The influence of cellular immunotherapy (CIT) courses on small cell lung cancer (SCLC) patients’ prognosis. (A) The median progression free survival (PFS) in the CIT ≥ 3 courses group was longer than that of the CIT < 3 courses group (9.5 vs. 2 months), although this difference was not significant (P = 0.057). (B) The median overall survival (OS) in the CIT ≥ 3 courses group was significantly longer than that of patients in the CIT < 3 courses group (23 vs. 9 months; P = 0.020)

Back to article page